Acutaas Chemicals Limited
Financial trend (100/100) does the heavy lifting; valuation (0/100) is the drag.
ExpensiveOvervaluedAcutaas Chemicals Limited earns a Hold from StocksWizard, with a blended score of 45/100. We put fair value near ₹1,552.45; at ₹3,104.9 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 93.2x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 16% below its 52-week high of ₹3,694.8 and 143% above the low of ₹1,279.4. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹2,390.78 implies about 23% downside across 9 analysts. It clears 8 of 13 investability checks, with durability 98, valuation 0 and momentum 60 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,241.96.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-15.97% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 23.5%
- Pass: Low debt (D/E < 0.5): 0.02x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 40%
- Pass: Earnings growing: 106%
- Pass: Net margin ≥ 10%: 26.6%
- Pass: Current ratio > 1.5: 3.82
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 71.79
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter38.3%
- Institutions28.4%
- Public & other33.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (23.5%).
- Lightly leveraged balance sheet.
- Healthy profit margin (26.6%).
- Financially solid — Altman Z 71.79.
Opportunities
- Earnings growing (106% YoY).
- Revenue growing (40% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Acutaas Chemicals Limited
Acutaas Chemicals Limited researches, manufactures, and sells pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients used in anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant drugs. The company also produces specialty chemicals for battery chemicals and personal care applications. It operates in India and internationally.
Acutaas Chemicals Limited — frequently asked questions
Is Acutaas Chemicals Limited a buy, hold or sell?
StocksWizard currently rates Acutaas Chemicals Limited (ACUTAAS) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Acutaas Chemicals Limited's fair value?
Our blended DCF and relative-valuation model estimates Acutaas Chemicals Limited's fair value at about ₹1,552.45, versus a current price of ₹3,104.9 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Acutaas Chemicals Limited financially healthy?
Acutaas Chemicals Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Acutaas Chemicals Limited's share price performed?
Acutaas Chemicals Limited is up 17% over three months, and last traded at ₹3,104.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.